Technology News and Research

RSS

Susan G. Komen for the Cure, OCNA urge FDA to allow use of Avastin

Susan G. Komen for the Cure and the Ovarian Cancer National Alliance today urged the U.S. Food and Drug Administration to continue to allow the use of the drug bevacizumab, commonly known as Avastin, for metastatic breast cancer patients, noting that it is effective for some patients and warning of a chilling effect on new drug development if approval is withdrawn.

13 Aug 2010

Cox Business light-speed computer connection provides TGen with fastest supercomputer link

A Cox Business light-speed computer connection coupled with advanced, military-grade technology now provides Translational Genomics Research Institute with the nation's fastest supercomputer link among life-sciences facilities.

13 Aug 2010

Travelers launches MedFirst to address new combination of risks in medical technology industry

The evolution of software and electronics for medical devices and the transferring of electronic personal identity records is creating a new combination of risks in the medical technology industry. To address these risks, Travelers announces MedFirstSM - a combination of three liability coverages packaged in a single insurance policy: products/completed operations liability, errors & omissions and information security liability.

13 Aug 2010

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

A significant milestone has been reached in the development of a new therapy for patients suffering from coronary artery disease. On July 27, 2010 the BIOTRONIK DREAMS (Drug Eluting Absorbable Metal Scaffold) was successfully implanted in the first patient by Prof. Dr. Michael Haude at the Lukaskrankenhaus in Neuss, Germany as part of the first-in-man clinical study BIOSOLVE-I.

13 Aug 2010

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

Quick-Med Technologies, Biosara sign development agreement

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has signed a development agreement with Biosara Corporation, a medical device company targeting wound dressings for major medical and healthcare providers, along with the multi-billion dollar organized sports athlete markets.

13 Aug 2010

PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

Ario Khoshbin, President of Prollenium Medical Technologies Inc., a privately held specialty medical device company, reported today that his firm will continue to record strong year on year gains in revenues and profitability for its 2010 Fiscal Year ending June 30th. Over the past five years, Prollenium has recorded aggregate revenue growth of more than 524% ranking it amongst Canada's fastest growing firms.

13 Aug 2010

SANUWAVE second-quarter revenues decrease to $117,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and six months ended June 30, 2010 and provided a business update.

13 Aug 2010

First Edition: August 13, 2010

Today's headlines explore a variety of health policy issues, ranging from consumer protections regarding benefit rights to the cost of electronic medical records.

13 Aug 2010

General Dynamics awarded $80.3M contract to support HHS Early Retiree Reinsurance Program

General Dynamics Information Technology's ViPS, part of its Health IT Solutions business sector, has been awarded a contract to support the Department of Health and Human Services (HHS) Early Retiree Reinsurance Program (ERRP). The total potential contract value is $80.3 million over four years if all options are exercised.

13 Aug 2010

EUROPEAN BIOTECHNICA AWARD finalists announced

The names of the finalists in this year's EUROPEAN BIOTECHNICA AWARD have been announced. The companies Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium) have made it through to the final round.

13 Aug 2010

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

UMass Memorial Medical Center in Massachusetts has selected the CytoCare™ robot from McKesson to automate the compounding of intravenous (IV) drugs. The robotic technology will enable the 830-bed facility to more safely prepare hazardous IVs, protecting both their patients and their staff from exposure risks.

13 Aug 2010

NewCardio second-quarter net loss decreases to $1.5 million

NewCardio, Inc., a cardiac diagnostic technology provider, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

New implantable device to prevent sudden cardiac arrest

Northwestern Memorial Hospital heart rhythm specialists recently gave a 34-year-old man a makeshift paramedic—who's always on duty—inside of his chest by implanting a device that did not require X-ray assistance and the usual snaking of wires leading to the heart. In fact, the innovative device rests just beneath the surface of the skin and its components are positioned using the patient's own anatomical landmarks.

13 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders.

13 Aug 2010

Kibow to support KDAE week for educating policymakers about kidney disease

Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).

13 Aug 2010

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Guided Therapeutics, Inc. today announced its operating results for the second quarter and first six months of 2010.

13 Aug 2010

CLC bio, PSSC Labs announce new turnkey solution for full-genome assembly and analysis

Today, CLC bio and PSSC Labs announced a new turnkey solution, CLC Genomics Factory, for assembly, read mapping, and subsequent downstream analysis of very large amounts of high-throughput DNA and RNA sequencing data. Built as a high-performance bioinformatics appliance, CLC Genomics Factory comes in three different sizes with varying numbers of compute nodes, capable of processing the data output from up to 10 Illumina HiSeq2000 or 7 Life Technologies SOLiD 4 systems.

13 Aug 2010

Technology News and Research

Susan G. Komen for the Cure, OCNA urge FDA to allow use of Avastin

Cox Business light-speed computer connection provides TGen with fastest supercomputer link

Travelers launches MedFirst to address new combination of risks in medical technology industry

BIOTRONIK DREAMS implanted in first patient as part of BIOSOLVE-I clinical study

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

Quick-Med Technologies, Biosara sign development agreement

PROFIT magazine ranks Prollenium as one of Canada's Fastest Growing Companies

SANUWAVE second-quarter revenues decrease to $117,000

First Edition: August 13, 2010

General Dynamics awarded $80.3M contract to support HHS Early Retiree Reinsurance Program

EUROPEAN BIOTECHNICA AWARD finalists announced

UMass Memorial selects McKesson's CytoCare robot to automate compounding of hazardous IV drugs

NewCardio second-quarter net loss decreases to $1.5 million

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

New implantable device to prevent sudden cardiac arrest

Neurologix second-quarter net loss increases to $4.5 million

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Kibow to support KDAE week for educating policymakers about kidney disease

Guided Therapeutics second-quarter service revenue increases to $0.8 million

CLC bio, PSSC Labs announce new turnkey solution for full-genome assembly and analysis

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News